ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

January 29, 2013 updated by: AstraZeneca

Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

3858

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amstetten, Austria
        • Research Site
      • Bad Ischl, Austria
        • Research Site
      • Baden, Austria
        • Research Site
      • Bregenz, Austria
        • Research Site
      • Bruck/Mur, Austria
        • Research Site
      • Dornbirn, Austria
        • Research Site
      • Eisenstadt, Austria
        • Research Site
      • Feldbach, Austria
        • Research Site
      • Feldkirch, Austria
        • Research Site
      • Freistadt, Austria
        • Research Site
      • Fuerstenfeld, Austria
        • Research Site
      • Gmuend, Austria
        • Research Site
      • Graz, Austria
        • Research Sites
      • Guessing, Austria
        • Research Site
      • Hainburg, Austria
        • Research Site
      • Hartberg, Austria
        • Research Site
      • Hollabrunn, Austria
        • Research Site
      • Horn, Austria
        • Research Site
      • Innsbruck, Austria
        • Research Site
      • Judenburg, Austria
        • Research Site
      • Kirchdorf, Austria
        • Research Site
      • Klagenfurt, Austria
        • Research Site
      • Klosterneuburg, Austria
        • Research Sites
      • Kufstein, Austria
        • Research Site
      • Leoben, Austria
        • Research Site
      • Linz, Austria
        • Research Sites
      • Melk, Austria
        • Research Site
      • Mistelbach, Austria
        • Research Site
      • Moedling, Austria
        • Research Site
      • Neunkirchen, Austria
        • Research Site
      • Oberpullendorf, Austria
        • Research Site
      • Oberwart, Austria
        • Research Site
      • Ried im Innkreis, Austria
        • Research Site
      • Rohrbach, Austria
        • Research Site
      • Rottenmann, Austria
        • Research Site
      • Salzburg, Austria
        • Research Site
      • Schaerding, Austria
        • Research Site
      • Scheibbs, Austria
        • Research Site
      • Schladming, Austria
        • Research Site
      • Schwarzach/Pongau, Austria
        • Research Site
      • Spittal/Drau, Austria
        • Research Site
      • St. Poelton, Austria
        • Research Site
      • St. Veit/Glan, Austria
        • Research Site
      • Steyr, Austria
        • Research Site
      • Tulln, Austria
        • Research Site
      • Vienna, Austria
        • Research Sites
      • Villach, Austria
        • Research Site
      • Voecklabruck, Austria
        • Research Site
      • Waidhofen/Thaya, Austria
        • Research Site
      • Wels, Austria
        • Research Site
      • Wolfsberg, Austria
        • Research Site
      • Zams, Austria
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.
  • At least 6 lymph nodes examined.
  • Good or intermediate tumour differentiation.
  • <6 weeks before start of adjuvant therapy.
  • Oestrogen or Progesterone positive

Exclusion Criteria:

  • Premenopausal.
  • Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
  • In-situ/T4 carcinoma.
  • Age >80 years.
  • World Health Organisation performance index >3.
  • Serious accompanying diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.

Secondary Outcome Measures

Outcome Measure
To assess the difference in event free survival & overall survival (subject to stand-alone or combined/meta-analysis) plus side effects between postmenopausal women with HR+ve early BC who switched from tam to anastrozole and those who continued on tam.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: AstraZeneca Austria Medical Director, MD, AstraZeneca
  • Principal Investigator: Raimund Jakesz, MD, Austrian Breast and Colorectal Cancer Study Group

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 1996

Primary Completion (Actual)

June 1, 2009

Study Completion (Actual)

June 1, 2009

Study Registration Dates

First Submitted

February 13, 2006

First Submitted That Met QC Criteria

February 13, 2006

First Posted (Estimate)

February 15, 2006

Study Record Updates

Last Update Posted (Estimate)

January 30, 2013

Last Update Submitted That Met QC Criteria

January 29, 2013

Last Verified

January 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe